Expensive and softening.

Trading above fair value while the fundamentals weaken — little to like right now.

Price $1443.50 taken 2026-11-15 · market cap about $1.3T
Fair value $82 range $51 to $130 · from the FY25 annual report
Margin of safety −94%, above fair value no margin of safety · the price sits above fair value

The five checks

2 good · 3 warning

  • Warning
    Overvalued
    Fair value ~$82 vs $1444 — trading 94% above what the math supports.
  • Warning
    Price assumes a big acceleration
    You'd need ~39%/yr free-cash-flow growth to justify today's price; it has done 16.1%/yr lately.
  • Good
    Revenue still growing
    Up 44.7% last year — demand isn't the problem.
  • Good
    Cash flow compounding
    Free cash flow up ~16.1%/yr — the engine is growing.
  • Warning
    Heavy debt load
    Net debt of $35B — roughly 6× annual free cash flow. This changes the risk picture.

Price against fair value

What today's price assumes

Hold the price fixed and work backwards: how fast would free cash flow have to grow for $1,444 to make sense?

The price needs ~39% a year
Eli Lilly has delivered 16.1% a year over the last three years

Price assumes a big acceleration.

Where this number comes from →

How fair value is calculated

No analyst forecasts, no black box, no AI. Six lines from the filing to the answer.

  1. Free cash flow, typical yearThe five-year norm, from the annual reports$6B
  2. Ten years of it, growing 5% a year, each counted 9% lessThe same growth and discount for every company$47B
  3. Everything after year tenGrowing 2.5% a year, counted the same way+ $62B
  4. The business, in today's money$109B
  5. Subtract net debtBorrowings and finance leases less cash and securities− $35B
  6. Divide by the shares on file÷ 0.8993B

Fair value per share$82

If our assumptions are wrong

Fair value per share under a faster or slower decade, and a gentler or harsher discount. The corners are where the $51 to $130 range comes from.

3% growth5% growth7% growth
8% discount$84$105$130
9% discount$65$82$102
10% discount$51$65$82

The blue cell is the published method. Every cell sits below today’s price.

Free cash flow, ten years

$ billions · Form 10-K

$3.8B FY16 $4.5B FY17 $4.3B FY18 $3.8B FY19 $5.1B FY20 $6.1B FY21 $5.7B FY22 $0.8B FY23 $3.8B FY24 $9.0B FY25
  1. FY25 $9.0B
  2. FY24 $3.8B
  3. FY23 $0.8B
  4. FY22 $5.7B
  5. FY21 $6.1B
  6. FY20 $5.1B
  7. FY19 $3.8B
  8. FY18 $4.3B
  9. FY17 $4.5B
  10. FY16 $3.8B

What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.

How this was built. Every figure is computed from Eli Lilly and Company's SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Fair value is based on typical free cash flow over the last five years ($5.7B), not the latest year ($9.0B), which sat 57% above the company's own norm. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. We subtract net debt from the value of the business — for Eli Lilly that is about $35B, or $39 per share. Fundamentals are from the FY25 annual report and change only when a new one is filed. Price of $1443.50 taken 2026-11-15 (Google Finance, manual entry, 2026-11-13) — it is not live and does not move during the day.

Read Eli Lilly another way

TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →